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ABSTRACT 
Benzo[a]pyrene (BaP) is a human carcinogen requiring metabolic activation prior to reaction 
with DNA. Cytochrome P450 (CYP) 1A1 is the most important hepatic and intestinal enzyme 
in both BaP activation and detoxification. CYP1A2 is also capable of oxidizing BaP, but to a 
lesser extent. The induction of CYP1A1/2 by BaP and/or β-naphthoflavone in liver and small 
intestine of rats was investigated. Both BaP and β-naphthoflavone induced CYP1A expression 
and increased enzyme activities in both organs. Moreover, the induction of CYP1A enzyme 
activities resulted in an increase in formation of BaP-DNA adducts detected by 32P-
postlabeling in rat liver and in the distal part of small intestine in vivo. The increases in 
CYP1A enzyme activity were also associated with bioactivation of BaP and elevated BaP-
DNA adduct levels in ex vivo incubations of microsomes of both organs with DNA and BaP. 
These findings indicate the stimulation effects of both compounds on BaP-induced 
carcinogenesis.  
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Abbreviations: AHR, aryl hydrocarbon receptor; BaP, benzo[a]pyrene; BCIP, 5-bromo-4-
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dihydrodiol-9,10-epoxide; CYP, cytochrome P450;  dG-N2-BPDE, 10-(deoxyguanosin-N2-
yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene;  DMSO, dimethyl sulfoxide; EROD, 
7-ethoxyresorufin O-deethylation; NBT, nitro-blue tetrazolium chloride; mEH, microsomal 
epoxide hydrolase;  MROD, 7-methoxyresorufin O-deethylation; PAH, polycyclic aromatic 
hydrocarbon; RAL, relative adduct labeling; TLC, thin-layer chromatography ; SDS, sodium 
dodecyl sulfate.  
 
1. Introduction 
Benzo[a]pyrene (BaP) is a polycyclic aromatic hydrocarbon (PAH) and has been classified as 
human carcinogen (Group 1) by the International Agency for Research on Cancer (IARC, 
2010). BaP and other PAHs are produced mainly by incomplete combustion of organic matter 
and are ubiquitous in the environment, leading to measurable background levels of exposure 
in the general population (IARC, 2010). Beside the inhalation of polluted air, the main 
sources of exposure are tobacco smoke and diet (Baird et al., 2005; Hamouchene et al., 2011; 
Phillips and Venitt, 2012). Chronic exposure of laboratory animals to BaP has been associated 
with the development of cancer, primarily in the skin, stomach and lungs (IARC, 2010). 
BaP requires metabolic activation catalyzed by cytochrome P450 (CYP) enzymes prior to 
reaction with DNA (Baird et al., 2005). Of the CYP enzymes, CYP1A1 is one of the most 
important enzymes in the metabolic activation of BaP to species forming DNA adducts (Baird 
et al., 2005; Hamouchene et al., 2011), in combination with microsomal epoxide hydrolase 
(mEH). First, CYP1A1 oxidizes BaP to an epoxide that is then converted to a dihydrodiol by 
mEH (i.e. BaP-7,8-dihydrodiol); then further bioactivation by CYP1A1 leads to the ultimately 
reactive species, BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, 
forming adducts preferentially at guanine residues (Fig. 1). The 10-(deoxyguanosin-N2-yl)-
7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE) adduct is the major 
product of BPDE reaction with DNA in vitro and in vivo (Phillips and Venitt, 2012).  
BaP is, however, oxidized also to other metabolites such as the other dihydrodiols, BaP-
diones and hydroxylated metabolites (Bauer et al., 1995; Chun et al., 1996; Kim et al., 1998; 
Jiang et al., 2001; Zhu et al., 2008). Even though most of these metabolites are detoxification 
products, BaP-9-ol is a precursor of 9-hydroxy-BaP-4,5-epoxide which can form another 
adduct with deoxyguanosine (Fig. 1) (Schoket et al., 1989; Nesnow et al., 1993; Fang et al., 
2003). Thus, the levels and activities of CYP1A1 seem to be crucial for the initiation of BaP-
mediated carcinogenesis. 
The expression of CYP1A1 is known to be up-regulated by the aryl hydrocarbon receptor 
(AHR) and BaP can bind to and activate AHR thereby enhancing its own metabolic activation 
(Nebert et al., 2004). Furthermore, beside BaP itself, additional AHR ligands that induce 
CYP1A1 can modulate BaP activation. Therefore, here we investigated the effect of the 
flavonoid β-naphthoflavone (BNF), an inducer of this enzyme, and another member of the 
CYP1A subfamily, CYP1A2, which can to some degree also participate in BaP activation 
(Bauer et al., 1995), on BaP-derived DNA adduct formation in rat liver and small intestine. 
Expression levels and activities of both CYP1A enzymes in these organs were also examined. 
The electrochemical method of Western blotting was used to evaluate CYP1A1 and/or 1A2 
expression, whereas DNA adduct formation was investigated by the thin-layer 
chromatography (TLC)-32P-postlabeling method. 
 
2. Materials and methods  
 
2.1. Animal experiments and isolation of microsomes 
All animal experiments were conducted in accordance with the Regulations for the Care and 
Use of Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in 
compliance with the Declaration of Helsinki. Male Wistar rats (150 g,  AnLab, Czech 
Republic), were housed in groups of 3 in wire cages at 22°C with a 12 hr light/dark period 
and ad libitum diet (ST-1 diet from Velaz, Czech Republic) and water access. Tested 
compounds dissolved in sunflower oil (1 ml), BNF (60 mg/kg b.w.) and BaP (150 mg/kg 
b.w.) were administered p.o. by gastric gavages in a single dose. BaP was applied 72 hr after 
administration of a single dose of BNF. The control group was treated with 1 ml of sunflower 
oil only. The rats were sacrificed 24 hr after the last treatment. Microsomes were prepared 
from sections of small intestine and the whole liver immediately after sacrificing the rats, as 
described previously (Krizkova et al., 2008; Hodek et al., 2011). Small intestine was removed 
~2 cm under the stomach, divided into two parts (proximal and distal), each 15-20 cm long. 
Tissues of 3 rats were pooled to isolate microsomes. Microsomal fractions were stored at 
−80°C until analysis. Protein concentrations in the microsomal fractions were assessed using 
the bicinchoninic acid protein assay with bovine serum albumin as a standard (Weichelman et 
al., 1988). The concentration of CYP was estimated according to Omura and Sato (1964) 
based on the absorption of the complex of reduced CYP with carbon monoxide. 
 
2.2. Determination of CYP1A protein levels by Western blotting  
CYP1A1 and 1A2 were detected by the electrochemical method of Western blotting on 
Immobilon-P membrane (Millipore, Bedford, MA) using specific chicken anti-CYP1A1/2 and 
anti-CYP1A2 antibodies prepared as described previously (Stiborová et al., 2002; Hodek et 
al., 2013). For sodium dodecyl sulfate (SDS)-electrophoresis (8% polyacrylamide gel) 30 µg 
and 15 µg protein/well of small intestine and liver microsomes, respectively, was applied. 
Western blotting was carried out as described earlier (Krizkova et al., 2008; Hodek et al., 
2011; Stiborová et al., 2002; Hodek et al., 2013; Stiborová et al., 2002; Hodek et al., 2013; 
Macova et al., 2013; Vranova et al., 2013). Visualization was performed using an anti-chicken 
IgG alkaline phosphatase-conjugated antibody and nitro-blue tetrazolium chloride (NBT)/5-
bromo-4-chloro-3'-indolyphosphate p-toluidine salt (BCIP) tablets containing 10 mg substrate 
for alkaline phosphatase. 
 
2.3. Measurement of CYP1A1 and 1A2 enzyme activities  
Each microsomal sample was analyzed for specific CYP1A1 and 1A2 activities by 
monitoring the following reactions: 7-ethoxyresorufin O-deethylation (EROD) (CYP1A1/2) 
and 7-methoxyresorufin O-deethylation (MROD) (CYP1A2), according to the method 
described by Burke and Mayer (1974). Briefly, incubation mixtures, containing the final 
volume of 150 µl, consisted of 100 mM potassium phosphate buffer (pH 7.4), 0.5 mM 
NADPH, 0.5 mg of microsomal protein and 2.2 µM 7-ethoxyresorufin (7-methoxyresorufin) 
(dissolved in 1.5 µl dimethyl sulfoxide, DMSO). The reaction was initiated by adding 
NADPH. The formation of resorufin was continuously measured on luminescence 
spectrometer (PerkinElmer LS-55 equipped with 96-well plate reader) for 10 minutes at room 
temperature by monitoring its fluorescence (excitation and emission wavelengths of 530 and 
585 nm, respectively) (Stiborová  et al., 2006; Krizkova et al., 2008; Hodek et al., 2011; 
Vranova et al., 2013). The dealkylation rate was estimated on the basis of a resorufin standard 
curve. 
 
2.4. BaP-DNA adduct analysis by 32P-postlabeling 
The DNA was isolated from liver and small intestine by standard phenol/chloroform 
extraction (Stiborová et al., 2006). DNA adducts formed by BaP were determined by 32P-
postlabeling analysis using the nuclease P1 enrichment version (Stiborová et al., 2006; 
Poljakova et al., 2013), and thin-layer chromatography (TLC) was performed as described 
(Arlt et al., 2008; 2012). After chromatography, TLC sheets were scanned using a Packard 
Instant Imager (Dowers Grove, USA) and DNA adduct levels (RAL, relative adduct labeling) 
were calculated as described (Stiborová et al., 2006; Poljakova et al., 2013). Results were 
expressed as DNA adducts/108 nucleotides.  
 
2.5 BaP-DNA adduct formation in vitro and their analysis 
Incubation mixtures used to assess DNA adduct formation by BaP activated with microsomes 
isolated from rat liver and small intestine consisted of 50 mM potassium phosphate buffer (pH 
7.4), 1 mM NADPH, 0.5 mg of microsomal proteins and 0.5 mg of calf thymus DNA in a 
final volume of 750 µl. The reaction was initiated by adding 0.1 mM BaP (dissolved in 7.5 µl 
DMSO). Incubations at 37°C were carried out for 90 min; BaP-DNA adduct formation was 
linear up to 120 min (Arlt et al., 2008). Control incubations were carried out either without 
microsomes, without NADPH, without DNA, or without BaP. After the incubation, DNA was 
isolated from the residual water phase by the phenol/chloroform extraction method and BaP-
DNA adducts analyzed with the nuclease P1 version of the 32P-postlabeling technique as 
described (Stiborová et al., 2006; Arlt et al., 2008; 2012; Poljakova et al., 2013). 
 
2.6 Statistical analyses 
For statistical data analysis we used Student’s t-test. All P-values are two-tailed and 
considered significant at the 0.05 level.  
3. Results and Discussion 
 
3.1. The effect of BaP and BNF on expression of CYP1A1/2 in rat liver and small intestine 
When rats were treated with BNF or BaP, an increase in expression levels of CYP1A1 and 
1A2 proteins determined with Western blotting was found in microsomes isolated from rat 
liver (Fig. 2), and this increase corresponded to EROD and MROD activities in these 
microsomes (Table 1). Pretreatment of rats with BNF prior to their treatment with BaP also 
resulted in elevated EROD and MROD activities in microsomes of this organ, however only 
the increase in CYP1A2 protein, but not CYP1A1, correlated with higher enzyme activity 
(see Fig. 2 and Table 1). Now, we cannot explain this phenomenon. The measurement of 
CYP1A1 activity seems to be more suitable to investigate the changes in CYP1A1 than 
determination of the CYP1A1 protein levels by Western blotting. 
In microsomes of the proximal and distal parts of small intestine, BaP and BNF also 
induced expression of CYP1A1 and its activity, but treatment of rats with BaP had a higher 
induction effect on this enzyme than their pretreatment with BNF prior to treatment with BaP. 
The CYP1A1 expression levels and its specific activity (EROD) in small intestine were 
higher in its proximal part than in its distal part (Fig. 3 and Table 2). 
 
3.2. The effect of BaP and BNF on BaP-DNA adduct formation in rat liver and small intestine 
Treatment of rats with a single dose of BaP resulted in formation of three BaP-derived DNA 
adducts (assigned as adduct spots 1-3 in Fig. 4A and 4B) detectable by 32P-postlabeling in the 
liver and the proximal and distal parts of the small intestine. Two of these adducts were 
tentatively identified to be dG-N2-BPDE (adduct spot 2) (Arlt et al., 2008; 2012) and the 
adduct derived from a reaction of deoxyguanosine in DNA with 9-hydroxy-BaP-4,5-epoxide 
(adduct spot 1) (Fig. 1) (Schoket et al., 1989; Nesnow et al., 1993; Fang et al., 2003). This 
BaP metabolite is bound to the exocyclic amino group of a guanine residue, and the site of 
attachment is most likely either the 4 or the 5 position on the BaP-4,5-epoxide (Fang et al., 
2003). A structure of another BaP-DNA adduct (adduct spot 3) has not been characterized as 
yet.  
Up to 4.6-fold higher levels of BaP-DNA adducts were found in the small intestine than 
in the liver (Table 3). Furthermore, significantly higher levels of BaP-DNA adducts 2 and 3 
were found in the proximal part of the small intestine than in its distal part, whereas levels of 
BaP-DNA adduct 1 in these parts of small intestine did not change. Pretreatment of rats with 
the CYP1A inducer BNF led to an increase in all BaP-DNA adduct levels in the liver and, to a 
lesser extent, in the distal part of the small intestine. However, almost no effect of this 
pretreatment was found on BaP-DNA adduct formation in the proximal part of small intestine 
(Table 3). The increase in levels of BaP-DNA adducts in the liver correlated with CYP1A1 
and 1A2 enzyme activities in this organ (compare Tables 1 and 3). 
Interestingly, when BaP was incubated with microsomes isolated from liver and small 
intestine of rats treated with BaP or with BNF prior to BaP treatment, only two BaP-DNA 
adducts were generated (see adduct spots 1 and 2 in Fig. 4C and 4D). Hence, formation of 
BaP-DNA adduct 3 found in vivo should be mediated not only by BaP activation with CYP 
enzymes present in the membrane of endoplasmic reticulum, but probably also by additional 
enzymes. Moreover, in contrast to results found in vivo, higher levels of BaP-DNA adducts 
were formed in ex vivo incubations of BaP and DNA with hepatic microsomes relative to 
microsomes of the small intestine (Table 4). Pretreatment of rats with BNF increased 
efficiencies of hepatic microsomes to generate BaP-DNA adducts (up to 2.7-fold), but either 
no or a low increase in efficacy of small intestine microsomes to form BaP-DNA adducts was 
found.  
The levels of BaP-DNA adducts formed in DNA incubated with BaP and microsomes of 
liver corresponded to CYP1A1/2 activities (EROD and MROD) found in these microsomes 
(Tables 1 and 4). Likewise, higher amounts of BaP-DNA adducts formed in microsomes of 
the proximal than in distal part of the small intestine correlated with expression levels of 
CYP1A1 and its enzyme activities in these microsomes (Fig. 3, Tables 2 and 3). However, 
whereas a minor, but significant, increase in BaP-DNA adduct formation was found in 
microsomes of the distal part of small intestine caused by pretreatment of rats with BNF prior 
to BaP exposure, no increase in expression of CYP1A1 and its enzyme activity was detected 
in these microsomes (Fig. 3, Tables 1, 2 and 4). In addition, the higher levels of BaP-DNA 
adducts found in the small intestine than in the liver in vivo contrasted with almost 70-fold 
higher CYP1A1 activities in liver microsomes relative to microsomes of the small intestine 
(Figures 1 and 2 and Table 4).  
All these results suggest that not only the activity of CYP1A1 (and/or CYP1A2 in the 
liver) and their induction by BaP or BNF, but also additional factors influence BaP-DNA 
adduct formation in vivo in rats. This finding is consistent with suggestions of Uno et al. 
(2001; 2004; 2006) that the level of BaP-DNA adducts in cells depends not only on the 
metabolism of BaP by phase I enzymes (activation) to reactive DNA-binding species and/or 
on BaP-induced expression of the enzymes involved in BaP activation (i.e. CYP1A1). Several 
studies demonstrated a rather enigmatic role of CYP 1A1 in BaP activation metabolism in 
vivo. The controversial results have been found, showing a more important role of CYP1A1 in 
vivo in BaP detoxification than in its activation (Uno et al., 2001; 2004; 2006; Arlt et al., 
2008; 2012). Indeed, Uno et al. (2001) showed that absence of the Cyp1a1 enzyme protects 
the intact animal from BaP-mediated liver toxicity and death, by decreasing the formation of 
large amounts of toxic metabolites, whereas much slower metabolic clearance of BaP in 
Cyp1a1(-/-) mice leads to greater formation of BaP-DNA adducts. Using the Hepatic P450 
Reductase Null (HRN) and the Reductase Conditional Null (RCN) mouse model we also 
showed that hepatic CYP enzymes appear to be more important for detoxification of BaP in 
vivo (Arlt et al., 2008; 2012). In HRN and RCN mice NADPH:CYP oxidoreductase, the 
essential electron donor to CYPs is deleted specifically in hepatocytes, resulting in a decrease 
in hepatic CYP function (Henderson et al., 2003; Finn et al., 2007). We found however that 
the levels of dG-N2-BPDE adducts in livers of these mice treated with BaP were higher than 
in WT mice (Arlt et al., 2008; 2012). Therefore, these and other factors such as: (i) 
detoxification of reactive BaP metabolites by both phase I and phase II enzymes 
(conjugation), (ii) rate of repair of BaP-DNA adducts, and (iii) BaP-induced expression of 
genes of enzymes involved in BaP detoxification or in DNA damage response (Uno et al., 
2004; 2006), might also influence BaP-DNA adduct levels in vivo. However, the impacts of 
those factors on BaP-DNA adduct formation in the present study in vivo remain to be 
explored.  
The results of this study demonstrate that the administration of BNF, BaP or BNF 
prior to BaP treatment induces CYP1A enzymes in rat liver and the distal part of the small 
intestine which leads to increased BaP-DNA adduct formation. The results also indicate that 
the electrochemical method of Western blotting is a suitable tool in evaluating the expression 
of CYP1A enzymes which, besides other factors, contributes to the risk of BaP-induced 
cancer development in various organisms including humans.  
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Table 1. CYP1A1/2 (EROD) and 1A2 (MROD) activities in rat liver microsomes. Reaction 
rates are means of three parallel experiments ± SD. Comparison was performed by t-test 
analysis: *P < 0.05, **P < 0.01, ***P < 0.001, different to untreated (UT).  
 
   Liver microsomes  
                           Resorufin formation 
                (pmol resorufin/min/mg protein)  
      CYP1A1 - EROD      CYP1A2 - MROD 
   UT 
  21.5 ± 1.3                  38.3 ± 2.2  
   BNF 
      527.1 ± 41.2 **                210.3 ± 12.5 * 
   BaP 
       840.6 ± 57.6 **                337.5 ± 29.9 ** 
   BaP + BNF 
            1742.5 ± 113.3 ***               1024.7 ± 37.1 ** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. CYP1A1 (EROD) activity in microsomes of rat small intestite. Reaction rates are 
means of three parallel experiments ± SD.  Comparison was performed by t-test analysis: *P 
< 0.05, **P < 0.01, ***P < 0.001, different to untreated (UT). 
 
  Microsomes of small   
            intestine 
                          CYP1A1 - EROD  
               (pmol resorufin/min/mg protein) 
               proximal                distal 
   UT 
                    1.0 ± 0.1                   0.5 ± 0.05 
   BNF 
                120.5 ± 9.8 ***                 20.0 ± 1.7 * 
   BaP 
                279.1 ± 22.3 ***                 33.2 ± 2.9 ** 
   BaP + BNF 
                243.2 ± 19.5 ***                 23.7 ± 1.2 * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. BaP-DNA adduct formation in liver (A) and small intestine (B) of rats treated with 
BaP or with BaP and BNF. RAL - relative adduct labeling. Values are averages of three 
parallel experiments ± SD (Adduct 1, 2 and 3 see Fig 4). Comparison was performed by t-test 
analysis; *P < 0.05, **P < 0.01, ***P < 0.001, different from rats treated with BaP only. 
     
 DNA sample 
BaP-DNA adducts (RAL/107 nucleotides) 
Spot 1 Spot 2 Spot 3 Total 
 BaP 
 0.61 ± 0.06  1.00 ± 0.10  0.79 ± 0.08  2.40 ± 0.24 
 BaP + BNF 
 1.28 ± 0.13 1.75 ±  0.17  2.75 ± 0.27  5.78 ±0.58 
 Folds      2.10***       1.75***       3.48***        2.40*** 
 
 
DNA sample 
BaP-DNA adducts (RAL/107 nucleotides) 
Spot 1 Spot 2 Spot 3 Total 
BaP 
proximal 
  3.85 ± 0.38   2.82 ± 0.28  4.39 ± 0.44  11.06 ± 1.10 
   distal 
  4.40 ± 0.44   1.56 ± 0.15  1.64 ± 0.16   7.60 ± 0.76 
BaP + BNF 
proximal 
  5.15 ± 0.51   2.97 ± 0.30  3.96 ± 0.40 12.08 ± 1.21 
   distal 
  4.02 ± 0.40   1.85 ± 0.18  2.64 ± 0.26   8.51 ± 0.85 
Folds in proximal       1.34**        1.05        0.90         1.09 
Folds in distal       0.91        1.19**        1.61***         1.12* 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Table 4. BaP-DNA adducts formed by liver (A) and small intestine microsomes (B) from rats 
treated with BaP or with BaP and BNF. RAL - relative adduct labeling. Values are averages 
of three parallel experiments (Adduct 1 and 2 see Fig 4). Comparison was performed by t-test 
analysis; *P < 0.05, **P < 0.01, ***P < 0.001, different from rats treated with BaP only.   
       
 DNA sample 
BaP-DNA adducts (RAL/107 nucleotides) 
Spot 1 Spot 2 Total 
 BaP 
 3.91 ± 0.21 1.56 ± 0.12    5.47 ± 0.51 
 BaP + BNF 
 7.06 ± 0.65 4.15 ± 0.32  11.21 ± 0.95 
 Folds        1.81***       2.66***        2.05*** 
       
       
DNA sample 
BaP-DNA adducts (RAL/107 nucleotides) 
Spot 1 Spot 2 Total 
BaP 
proximal 
  0.93 ± 0.07   0.18 ± 0.02   1.11 ± 0.09 
   distal 
  0.19 ± 0.02   0.04 ± 0.01   0.23 ± 0.02 
BaP + BNF 
proximal 
  0.90 ± 0.07   0.13 ± 0.01   1.03 ± 0.1 
   distal 
  0.31 ± 0.03   0.07 ± 0.01   0.38 ± 0.04 
Folds in proximal         0.97        0.72        0.93 
Folds in distal         1.6*        1.75**        1.65* 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Legends to Figures 
Figure 1. Proposed pathways of biotransformation and DNA adduct formation of BaP 
catalyzed by CYP1A1 and mEH. The two-step activation process by CYP1A1 leading to 
the formation of the ultimately reactive species, 9-hydroxy-BaP-4,5-epoxide, that can 
react with deoxyguanosine in DNA (adduct 1) is shown in the left part of the figure. The 
typical three-step activation process with oxidation by CYP1A1 followed by hydrolysis 
by mEH leads to the ultimately reactive species, BPDE, forming the dG-N2-BPDE adduct 
(adduct 2) is shown in the right part of the figure.  
Figure 2. Immunodetection of induced CYP1A1 and 1A2 in liver microsomes from untreated 
(UT), or BNF, BaP or BaP and BNF (BaP+BNF) pretreated animals. Values are given as 
means of three parallel experiments. Comparison was performed by t-test analysis: *P < 
0.05, **P < 0.01, ***P < 0.001, different to UT.  
Figure 3. Immunodetection of induced CYP1A1 in microsomes isolated from the proximal 
and distal parts of small intestine of rat either untreated (UT), or treated with BNF, BaP or 
BaP and BNF (BaP+BNF). Values are given as means of three parallel experiments. 
Comparison was performed by t-test analysis: ***P < 0.001, different to UT.   
Figure 4. BaP-DNA adduct formation in rat liver (A) and small intestine (B) in vivo and in 
incubations of BaP and DNA with rat liver (C) and small intestine (D) microsomes ex 
vivo. DNA adducts were analyzed by the 32P-postlabeling method. 
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